4420456374_64a3d7e6aa_88_2

Top Ten most popular articles on Pharmafile.com this week

pharmafile | January 17, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Big Pharma, European Commission, FDA, Pakistan, Sanofi, Teva 

Pakistan is cracking down on corruption and has registered cases against 200 pharmaceutical companies, while in the US the FDA has move to authorise Blueprint Medicines’ kinase inhibitor Ayvakit (avapritinib) for the treatment of unresectable or metastatic gastrointestinal stromal tumours.

In Europe, Sanofi has revealed that the European Commission has expanded the existing label for Toujeo to include the treatment of children and adolescent patients with diabetes.

10. Pakistan registers cases against 200 pharmaceutical companies

The Punjab Quality Control Board has sent at least 74 cases to the drugs courts for prosecution, and has overall registered cases against 200 pharmaceutical companies.

9. US approval for Blueprint Medicines’ gastrointestinal stromal tumour therapy

The FDA has moved to authorise Blueprint Medicines’ kinase inhibitor Ayvakit (avapritinib) for the treatment of unresectable or metastatic gastrointestinal stromal tumour (GIST) in patients possessing a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation.

8. NICE shoots down Keytruda in head and neck cancer over data concerns

It has been revealed that NICE has chosen to reject MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) for routine use on the NHS as a treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC), citing uncertainty over the data provided by the manufacturer.

7. Sanofi secures expanded European approval for Toujeo in type 1 diabetes

Sanofi has revealed that the European Commission has expanded the existing label for Toujeo (insulin glargine 300 units/mL) to include the treatment of children and adolescent patients with diabetes, after the drug met its primary endpoint of non-inferiority compared to insulin glargine 100 units/mL (Gla-100).

6. Working Life Interview: Jean-Paul Kress, CEO of MorphoSys

An interview with the CEO of MorphoSys

5. MorphoSys and Incyte forge potential $1.1bn partnership to develop B cell malignancy drug candidate

MorphoSys and Incyte have joined together in a partnership to develop and commercialise the latter’s anti-CD19 antibody tafasitamab as a treatment for B cell malignancies, it has been announced.

4. Eli Lilly to boost immunology portfolio with $1.1bn Dermira acquisition

Eli Lilly has announced it has entered into an agreement to acquire Dermira, a biopharmaceutical firm focused on the development of therapies for chronic skin conditions, for the value of $1.1 billion.

3. Pfizer’s Ibrance combo authorised via the Cancer Drugs Fund for advanced breast cancer

NICE, the drug watchdog for England and Wales, has given its approval for Pfizer’s Ibrance (palbociclib) in combination with AstraZeneca’s Faslodex (fulvestrant) to be made available via the Cancer Drugs Fund as a treatment for advanced breast cancer.

2. Bayer and Exscientia to work together on AI in cardiovascular and oncology drug discovery

Bayer AG has partnered with Exscientia to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.

1. Biogen picks up Pfizer’s Phase 1 therapy for Alzheimer’s symptoms in potential $700m deal

Biogen has entered into an agreement with Pfizer to acquire the latter’s Phase 1 candidate PF-05251749 in order to develop it into a treatment for “behavioural and neurological symptoms across various psychiatric and neurological diseases”, it has emerged.

Related Content

blood_tests_pic

Innate Pharma announces drug researched with Sanofi receives FDA Fast Track Designation

Innate Pharma has announced that the drug jointly researched between itself and Sanofi has received US …

FDA approves ANDA of 20mg generic Nitisinone capsules

Analog Pharma and Dipharma have announced that the US Food and Drug Administration (FDA) has …

FDA approves Pfizer’s RSV vaccine for older adults

Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has …

Latest content